Renal dysfunction and atrial fibrillation recurrence following cardioversion

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 10, 2011, Pages 1092-1098

  Schmidt, Martin ^a   Daccarett, Marcos ^b   Rittger, Harald ^a   Marschang, Harald ^a   Holzmann, Stefan ^a   Jung, Philip ^c   Bojanic, Davor ^a   Ketteler, Markus ^a   Brachmann, Johannes ^a   Rieber, Johannes ^c  

^a KLINIKUM COBURG   (Germany)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

antiarrhythmic drugs; anticoagulation; atrial fibrillation; cardioversion; kidney dysfunction

Indexed keywords

AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SINUS RHYTHM;

AGED; ANALYSIS OF VARIANCE; ATRIAL FIBRILLATION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ELECTRIC COUNTERSHOCK; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; HEART CONDUCTION SYSTEM; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 80054718531     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2011.02069.x     Document Type: Article

References (34)

1. Benjamin EJ, Wolf PA, Dàgostino RB, Silbershatz H, Kannel WB, Levy D,: Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952. (Pubitemid 28446646)
2. Kannel WB, Wolf PA, Benjamin EL, Levy D,: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 82: 2N-9N. (Pubitemid 28507114)
3. Li H, Riedel R, Oldemeyer JB, Rovang K, Hee T,: Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy. Am J Cardiol 2004; 93: 45-48. (Pubitemid 38022031)
4. Alatawi F, Gurevitz O, White RD, Ammash NM, Malouf JE, Bruce CJ, Moon BJ, Rosales AG, Hodge D, Hammill SC, Gersh BJ, Friedman PA,: Prosepective, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic biphasic cardioversion of atrial fibrillation. Heart Rhythm 2005; 2: 328-337.
5. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ,: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839. (Pubitemid 40789940)
6. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D,: Tissue-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med 2001; 79: 76-102. (Pubitemid 32285333)
7. Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, Uemura J, Shibazaki K,: Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102: 1056-1059.
8. Vazquez E, Sanchez-Perales C, Borrego F, Borrego F, Garcia-Cortes MJ, Lozano C, Guzman M, Gil JM, Borrego MJ, PÄ - rez V,: Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J 2000; 140: 886-890.
9. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY,: Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol 2003; 4: 1-10. (Pubitemid 38809124)
10. Zebe H,: Atrial fibrillation in dialysis patients. Nephrol Dial Transplant 2000; 15: 765-768. (Pubitemid 30311991)
11. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S,: Risks associated with renal dysfunction in the coronary care unit. J Am Coll Cardiol 2000; 36: 679-684.
12. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL,: ACC/AHA/ESC 2006 guidelines for the mangagement of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2006; 48: 854-906. (Pubitemid 44175743)
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470. (Pubitemid 29135798)
14. Kang YS, Han KA, Han SY, Kim HK, Cha DR,: Characteristics of population with normal serum creatinine impaired renal function and the validation of a MDRD formula in a healthy general population. Clin Nephrol 2005; 63: 258-266. (Pubitemid 40542385)
15. Grambsch PM, Therneau TM,: Proportional hazards tests and diagonstics based on weighted residuals. Biometrika 1994; 81: 515 526.
16. Levey AS, Eckardt KU, Tsukamoto Y, Greene T, Rogers N, Roth D,: Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
17. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS,: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12. (Pubitemid 36043346)
18. Kannel WB, Wolf PA, Benjamin EJ, Levy D,: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 1998; 98: 946-952.
19. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B,: The severe cardiorenal syndrome: 'Guyton revisited.' Review. Eur Heart J 2005; 26: 11-17.
20. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD,: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402-1407.
21. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG,: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918. (Pubitemid 23006966)
22. Ehrlich JR, Hohnloser SH, Nattel S,: Role of angiotensin system and effects of its inhibition in atrial fibrillation: Clinical and experimental evidence. Eur Heart J 2006; 27: 512-518.
23. Casaclang-Verzosa G, Gersh BJ, Tsang TS,: Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008; 51: 1-11.
24. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE,: Prevention of atrial fibrillation by Renin-Angiotensin system inhibition: A meta-analysis. J Am Coll Cardiol 2010; 55: 2299-2307.
25. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G,: GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.
26. Schmidt M, Rieber J, Daccarett M, Marschang H, Sinha AM, Biggar P, Jung P, Ketteler M, Brachmann J, Rittger H,: Relation of recurrence of atrial fibrillation after successful cardioversion to renal function. Am J Cardiol 2010; 105: 368-372.
27. Upshaw CB,: Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Int Med 1997; 157: 1070-1076.
28. Xiong C, Sonnhag C, Nylander E, Wranne B,: Atrial and ventricular function after cardioversion of atrial fibrillation. Br Heart J 1995; 74: 254-260.
29. Tang WH, Mullens H,: Cardiorenal syndrome in decompensated heart failure. Heart 2010; 96: 255-260.
30. Schrier RW, Abraham WT,: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-585. (Pubitemid 29384167)
31. Cain ME, Curtis AB,: Editorial. Rhythm control in atrial fibrillation-One setback after another. N Engl J Med 2008; 358: 2725-2727. (Pubitemid 351860867)
32. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG, AFFIRM Investigators: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-1513. (Pubitemid 38420179)
33. Alatawi F, Gurevitz O, White RD, Ammash NM, Malouf JF, Bruce CJ, Moon BS, Rosales AG, Hodge D, Hammill SC, Gersh BJ, Friedman PJ,: Prosepctive, randomized comparison of two biphasic waveforms for the efficacy and safety of transthoracic biphasic cardioversion of atrial fibrillation. Heart Rhythm 2005; 2: 382-387. (Pubitemid 40443622)
34. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF,: Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-728.